ChemicalBook--->CAS DataBase List--->1231929-97-7

1231929-97-7

1231929-97-7 Structure

1231929-97-7 Structure
IdentificationBack Directory
[Name]

Abemaciclib
[CAS]

1231929-97-7
[Synonyms]

CS-814
abecilee
Abemaciclib
Abemaciclib D7
Abemaciclib D10
ABEMACICLIB BASE
Abemaciclib, >=98%
Abemaciclib Powder
Abemaciclib free base
CDK4/6 dual inhibitor
LY2835219 (free base)
LY-2835219 (free base)
LY 2835219 (free base)
LY2835219(Abemaciclib)
Abemaciclib (LY2835219)
Bemaciclib(LY2835219free base
LY2835219free base,Abemaciclib
abemaciclib(CDK 4/6 inhibitor)
Abemaciclib Mesylate (Verzenio)
Bemaciclib(LY2835219, abemaciclib)
ethyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-amine
inhibit,LY-2835219,LY 2835219,Abemaciclib,Inhibitor,Cyclin dependent kinase,CDK
LY2835219;LY-2835219;LY 2835219;ABEMACICLIB;CDK4/6 DUAL INHIBITOR;LY-2835219 FREE BASE
N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine
5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzimidazol-5-yl)pyrimidin-2-yl)amine
N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-1,3-benzodiazol-5-yl)pyrimidin-2-amine
N-(5-((4-Ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-amine
N-[5-[(4-Ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamine
2-Pyrimidinamine,N-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-
[Molecular Formula]

C27H32F2N8
[MDL Number]

MFCD22665744
[MOL File]

1231929-97-7.mol
[Molecular Weight]

506.59
Chemical PropertiesBack Directory
[Boiling point ]

689.3±65.0 °C(Predicted)
[density ]

1.32±0.1 g/cm3(Predicted)
[storage temp. ]

4°C, protect from light
[solubility ]

insoluble in H2O; ≥4.83 mg/mL in DMSO with gentle warming and ultrasonic; ≥6.34 mg/mL in EtOH with gentle warming
[form ]

solid
[pka]

7.69±0.10(Predicted)
[color ]

Off-white to yellow
[InChIKey]

UZWDCWONPYILKI-UHFFFAOYSA-N
[SMILES]

C1(NC2=NC=C(CN3CCN(CC)CC3)C=C2)=NC=C(F)C(C2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1
Safety DataBack Directory
[Symbol(GHS) ]

Health Hazard (GHS08)
GHS08
[Signal word ]

Danger
[Hazard statements ]

H373-H360-H410
[Precautionary statements ]

P273-P391-P501-P260-P314-P501
Hazard InformationBack Directory
[Characteristics]

Class: serine/threonine protein kinase
Treatment: Breast cancer
Oral bioavailability = 46%
Elimination half-life = 18 h
Protein binding = 95–98%
[Uses]

Abemaciclib is a potent and selective inhibitor of cyclin-dependent kinases, CDK4 and CDK6, as a method to inhibit the proliferation of cancer cells.
[Indications]

Abemaciclib is used to treat breast cancer that is estrogen receptor-positive (ER-positive) and HER2-negative. It can be taken by both men and women. Patients may be offered abemaciclib if they have:
Early primary breast cancer that the treatment team thinks has a higher risk of coming back (recurrence). Abemaciclib may be provided as an adjuvant treatment, meaning a treatment given after initial treatment, such as surgery;
Breast cancer that has spread to the tissues and lymph nodes around the chest, neck, and under the breastbone (locally advanced breast cancer);
Breast cancer has spread to other parts of the body, such as the bones, lungs, liver, or brain (secondary breast cancer).
[Biological Activity]

ly2835219 is an orally available cyclin-dependent kinase (cdk) inhibitor that targets the cdk4 (cyclin d1) and cdk6 (cyclin d3) cell cycle pathway, with potential antineoplastic activity. cdk4/6 dual inhibitor ly2835219 specifically inhibits cdk4 and 6, thereby inhibiting retinoblastoma (rb) protein phosphorylation in early g1. inhibition of rb phosphorylation prevents cdk-mediated g1-s phase transition, thereby arresting the cell cycle in the g1 phase, suppressing dna synthesis and inhibiting cancer cell growth. overexpression of the serine/threonine kinases cdk4/6, as seen in certain types of cancer, causes cell cycle deregulation.
[Biochem/physiol Actions]

LY2835219 (abemaciclib) was identified via compound and biochemical screening by scientists at Eli Lilly and Company Research Laboratories and selected for its biological activity and highly selective inhibition of the complexes CDK4/ cyclin D1 (IC50 =2 nmol/L) and CDK6/cyclin D1 (IC50 =10 nmol/L), with no activity against other CDK/cyclin complexes or cell-cycle-related kinases within the nanomolar ranges, except for inhibition of CDK9 at IC50 at least five times higher. The compound was shown to act as a competitive inhibitor of the ATP-binding domain of the CDK4 and CDK6 and to be 14 times more potent against CDK4 than against CDK6. In comparison to palbociclib and ribociclib, abemaciclib shows higher selectivity for the complex CDK4/cyclin D1, with IC50 values five times lower than those of the two other compounds[1].
[Mechanism of action]

Abemaciclib is a CDK4/6 inhibitor, and CDK4 and CDK6 proteins are closely related to stimulating cancer cell division and growth. Abemaciclib blocks the cell cycle and slows or stops cancer growth by binding to the ATP binding domain of CDK4 and CDK6, and it is 14 times more potent against CDK4 than against CDK6.
[Side effects]

Common side effects of abemaciclib include: gastrointestinal reactions (diarrhea, loss of appetite, nausea, vomiting, stomach pain and constipation); increased risk of infection (main symptoms include changes in body temperature, muscle aches, cough, headache, feeling cold and shivering, pain or burning when urinating); skin problems (rash, itchy and dry skin); bruises, bleeding gums or nosebleeds; difficulty breathing, paleness, taste changes, mouth pain, tiredness and weakness; hair loss. Serious side effects are fatal interstitial lung disease. In addition, abemaciclib can cause thrombotic coronary artery side effects when treating advanced breast cancer.
[Synthesis]

A concise total synthesis of CDK 4/6 inhibitor abemaciclib is described below. The synthesis uses a Suzuki coupling and a Hartwig–Buchwald amination to join three of the four subunits. The final step is a reductive amination utilizing Leuckart–Wallach conditions. Key to the Leuckart–Wallach reaction was the addition of trimethyl orthoformate to remove water formed during the reaction, allowing the reaction to complete[4].
Abemaciclib
[Enzyme inhibitor]

This oral cell cycle inhibitor (FWfree-base = 506.61 g/mol; FWmesylate-salt = 602.70 g/mol; CAS 1231930-82-7 (mesylate salt) ), also known as LY2835219 and N-[5-[ (4-ethyl-1-piperazinyl) methyl]-2-pyridinyl]-5- fluoro-4-[4-fluoro-2-methyl-1- (1-methylethyl) -1H-benzimidazol-6-yl]-2- pyrimidinamine, targets the cyclin-dependent kinase CDK4, or cyclin D1 (IC50 = 2 nM) and CDK6, or cyclin D3 (IC50 = 6 nM), inhibiting retinoblastoma (Rb) protein phosphorylation in early G1, thereby arresting the cell cycle in the G1, suppressing DNA synthesis, and inhibiting cancer cell growth. LY2835219 inhibits activation of AKT and ERK, but not mTOR.
[References]

[1] Silvia Paola Corona, Daniele Generali. “Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer.” Drug Design, Development and Therapy (2018): 321–330.
[2] “OS Trending Positive for Abemaciclib.” Cancer discovery 13 1 (2023): OF3.
[3] Erin R Scheidemann. “Resistance to abemaciclib is associated with increased metastatic potential and lysosomal protein deregulation in breast cancer cells.” Molecular Carcinogenesis (2024): 209–223.
[4] Michael O. Frederick, Douglas P. Kjell. “A synthesis of abemaciclib utilizing a Leuckart–Wallach reaction.” Tetrahedron Letters 56 7 (2015): Pages 949-951.
Spectrum DetailBack Directory
[Spectrum Detail]

Abemaciclib(1231929-97-7)1HNMR
1231929-97-7 suppliers list
Company Name: Beijing Hope Pharmaceutical Co., Ltd.  Gold
Telephone: 67886402 15600038801
Website: https://www.hopelife.cn/
Company Name: hongqing Huafeng Pharmaceutical Technology Co., LTD  Gold
Telephone: 23-67950001 13883380852
Website: http://www.cqhfpharm.com
Company Name: Hangzhou Cheminspire Technology Co., Ltd.  Gold
Telephone: 0571-89081561; 10006559855
Website: http://www.cheminspire.com
Company Name: INTERCHEMIE NANJING PHARMATECH CO., LTD  Gold
Telephone: 13656237714 13656237714;
Website: https://www.chemicalbook.com/ShowSupplierProductsList19089/0_EN.htm
Company Name: Hangzhou Chemtrue Bio-Tech Co.,Ltd.  Gold
Telephone: 19967494293
Website: www.chemtrue-bio.com
Company Name: Cangzhou Kangrui Medical Technology Co., LTD  Gold
Telephone: 18632776803
Website: https://www.chemicalbook.com/ShowSupplierProductsList1631868/0.htm
Company Name: CHANGZHOU PHARMACEUTICAL FACTORY  Gold
Telephone: 0519-88821493 18915891730
Website: www.czpharma.com
Company Name: Porton Pharma Solutions Ltd.  Gold
Telephone: 15169181595
Website: www.porton.cn
Company Name: Henan Continuing Fortune Pharmatech Co., Ltd.  Gold
Telephone: 18937270282 18937270282
Website: www.hyllpharmatech.com/
Company Name: Shanghai Boyle Chemical Co., Ltd.  
Telephone:
Website: www.boylechem.com
Company Name: Chembest Research Laboratories Limited  
Telephone: 021-20908456
Website: www.biochembest.com
Company Name: Energy Chemical  
Telephone: 400-0056266
Website: www.energy-chemical.com
Company Name: Nanjing Chemlin Chemical Co., Ltd  
Telephone: 025-83697070 13770331960
Website: www.echemlin.cn
Company Name: Dalian Meilun Biotech Co., Ltd.  
Telephone: 0411-62910999 13889544652
Website: http://www.meilunbio.com/
Company Name: T&W GROUP  
Telephone: 021-61551611 13296011611
Website: www.trustwe.com/
Company Name: S.Z. PhyStandard Bio-Tech. Co., Ltd.  
Telephone: 0755-4000505016 13380397412
Website: www.sincopharmachem.net
Company Name: Shanghai Topbiochem Technology Co., Ltd  
Telephone: 021-58170097
Website: www.topbiochem.com
Company Name: Shanghai MOF Chemical Tech Limited  
Telephone: 13661494087 18964793018
Website: www.chemicalbook.com/ShowSupplierProductsList15875/0_EN.htm
Tags:1231929-97-7 Related Product Information
700874-72-2 1194044-20-6 1234703-40-2 1254473-64-7 603288-22-8 209984-57-6 396129-53-6 946518-60-1 1262036-50-9 1454682-72-4 167465-36-3 892128-60-8 911222-45-2 1627696-51-8 154447-36-6 1082949-68-5